Radio frequency ablation devices market outlook, market size segmentation, drivers & trends, key players and regional analysis
OG Analysis presents a detail insight on radio frequency ablation devices market growth and records growth of 11.54% CAGR during the foreseen period.
The factors largely driving the radiofrequency ablation devices market include rising cases of cardio-patients diagnosed with atrial fibrillation augmented with large commercialization of new atrial fibrillation ablation technologies , and increasing clinical trials for increasing long-term procedural success.
Radio frequency ablation devices market growth also commensurate with the rise in arrhythmia burden and ongoing large number of medical technical advancements.
Biosense Webster SmartTouch and the Abbott TactiCath contact force sensing catheters have more likely become the standard in RF ablation technology.
Medtronic has announced FDA clearance of the Accurian RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues.
The radio frequency ablation devices market is segmented based on different radio frequency ablation product types, as RF generators, reusable products and disposable products. Further, the market is being analysed across distinctive applications including surgical oncology, cardiology & cardiac rhythm management, cosmetology, gynecology, and pain management and by key end-users as hospitals, ambulatory surgical centres, and others.
Regional analysis of radio frequency ablation devices market is across
South America & Central America
Middle East & Africa
Americas is among the lucrative regions of radio frequency ablation devices market followed by emerging economies including China, India, Brazil and others.
Cardiology & Cardiac rhythm management segment to project enormous radio frequency ablation devices market growth
The adoption of RFA has markedly increased over time for patients diagnosed with chronic ailments related to cardiovascular, coronary heart disease and atherosclerosis.
Radiofrequency ablation (RFA) has proven to be an effective optimize lesion formation and safe arrhythmia treatments.
In addition, the increased preference for radio frequency ablation devices is witnessed more owing to exceedingly low complications arising in incidence of coronary artery (CA) injury after RFA.
Key players majorly contributing towards radio frequency ablation devices value
Biosense Webster Inc. (A Subsidiary of Johnson & Johnson Inc.)
St. Jude Medical Inc.
Boston Scientific Corporation
Smith & Nephew
Galil Medical Inc. (Acquired By BTG International Ltd.)